Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; RESONATE Investigators. Byrd JC, et al. Among authors: barrientos jc. N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31. N Engl J Med. 2014. PMID: 24881631 Free PMC article. Clinical Trial.
MRD-directed therapy in CLL: ready for prime time?
Rhodes JM, Lopez CA, Barrientos JC. Rhodes JM, et al. Among authors: barrientos jc. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):413-420. doi: 10.1182/hematology.2023000441. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066928 Review.
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. Wang ML, et al. Among authors: barrientos jc. N Engl J Med. 2013 Aug 8;369(6):507-16. doi: 10.1056/NEJMoa1306220. Epub 2013 Jun 19. N Engl J Med. 2013. PMID: 23782157 Free PMC article. Clinical Trial.
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O'Brien SM. Furman RR, et al. Among authors: barrientos jc. N Engl J Med. 2014 Mar 13;370(11):997-1007. doi: 10.1056/NEJMoa1315226. Epub 2014 Jan 22. N Engl J Med. 2014. PMID: 24450857 Free PMC article. Clinical Trial.
Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.
James DF, Werner L, Brown JR, Wierda WG, Barrientos JC, Castro JE, Greaves A, Johnson AJ, Rassenti LZ, Rai KR, Neuberg D, Kipps TJ. James DF, et al. Among authors: barrientos jc. J Clin Oncol. 2014 Jul 1;32(19):2067-73. doi: 10.1200/JCO.2013.51.5890. Epub 2014 May 27. J Clin Oncol. 2014. PMID: 24868031 Free PMC article.
Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.
Claus R, Lucas DM, Ruppert AS, Williams KE, Weng D, Patterson K, Zucknick M, Oakes CC, Rassenti LZ, Greaves AW, Geyer S, Wierda WG, Brown JR, Gribben JG, Barrientos JC, Rai KR, Kay NE, Kipps TJ, Shields P, Zhao W, Grever MR, Plass C, Byrd JC. Claus R, et al. Among authors: barrientos jc. Blood. 2014 Jul 3;124(1):42-8. doi: 10.1182/blood-2014-02-555722. Epub 2014 May 27. Blood. 2014. PMID: 24868078 Free PMC article.
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC. Woyach JA, et al. Among authors: barrientos jc. N Engl J Med. 2014 Jun 12;370(24):2286-94. doi: 10.1056/NEJMoa1400029. Epub 2014 May 28. N Engl J Med. 2014. PMID: 24869598 Free PMC article.
Management of adverse events associated with idelalisib treatment: expert panel opinion.
Coutré SE, Barrientos JC, Brown JR, de Vos S, Furman RR, Keating MJ, Li D, O'Brien SM, Pagel JM, Poleski MH, Sharman JP, Yao NS, Zelenetz AD. Coutré SE, et al. Among authors: barrientos jc. Leuk Lymphoma. 2015;56(10):2779-86. doi: 10.3109/10428194.2015.1022770. Epub 2015 May 19. Leuk Lymphoma. 2015. PMID: 25726955 Free PMC article. Review.
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM. Wilson WH, et al. Among authors: barrientos jc. Nat Med. 2015 Aug;21(8):922-6. doi: 10.1038/nm.3884. Epub 2015 Jul 20. Nat Med. 2015. PMID: 26193343 Free PMC article. Clinical Trial.
77 results